BioSpace News Archive

Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced revised results of its pending rights offering.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that Michael Kauffman, MD, PhD, Chief Executive Officer of Karyopharm, will participate in a fireside chat at Baird’s 2020 Global Healthcare Conference and at the Morgan Stanley 18th Annual Global Healthcare Conference.

Treadwell Therapeutics announced the initiation of patient dosing in TWT-101, its Phase 1/2 study to evaluate its third therapeutic candidate, CFI-402411, an oral, first-in-class inhibitor of hematopoietic progenitor kinase 1 in patients with solid tumors as a monotherapy or in combination with PD1 pathway blockade.

ICON plc, a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations

Boehringer Ingelheim today announced the final analysis from GioTag, a real-world retrospective, observational study

Seneca Biopharma, Inc., a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, provided the following letter from Dr. Ken Carter, the Company’s Executive Chairman.

Belmont University, University of New Haven, Illinois State University, Virginia Tech, University of Memphis are 2020 top fundraising schools

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will be holding a virtual key opinion leader (KOL) event to discuss edasalonexent, currently in Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD), on Friday, September 11, . 2020 at 9:00am ET. The event will feature a discussion with Craig McDonald, M.D., Director, Neuromuscular Disease Clinics at UC

Applied DNA to Present at H.C. Wainwright 22 nd Annual Global Investment Conference on September 15

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will participate in the Wells Fargo Securities Healthcare Conference, a fully virtual management access conference, taking place September 9-10. President and Chief Executi